Apimeds Pharmaceuticals US Inc
APUS | AMEX
$2.88
-$0.33 (-10.28%)
At close: Oct 30, 2026, 3:59 PM ET
$3.14
+$0.26 (+9.03%)
Pre-market:
Nov 2, 2026, 6:10 AM ET
Market Data
Market Cap $4.35M
Enterprise Value $18.65M
Beta 0.15
Average Volume 2.72M
Shares Outstanding (Diluted) 1.63M
Shares Change YoY 1474.69%
Institutional Ownership 2.61%
Exchange AMEX
ISIN US03771D2018
Price Performance
Price Change 1M -42.4%
Price Change 3M -44.1%
Price Change 6M -84.7%
Price Change YTD -82.4%
Price Change 1Y -86.8%
Price Change 3Y N/A
Price Change 5Y N/A
1M CAGR (ann.) 70.1%
1Y CAGR (ann.) -85.2%
5Y CAGR (ann.) N/A
All-Time CAGR -74.0%
Valuation
PE Ratio -0.06
Forward PE N/A
PEG Ratio 0.00
Forward PEG 0.00
PS Ratio N/A
Forward PS N/A
PB Ratio 0.04
P/FCF Ratio -0.31
P/Adj. FCF Ratio -0.31
P/OCF Ratio -0.34
EV/Sales N/A
EV/EBIT -0.35
EV/EBITDA -0.35
EV/FCF -1.34
Earnings Yield -1711.5%
FCF Yield -320.2%
Adj. FCF Yield -321.2%
Financial Health
Net Debt $14.3M
Total Debt $14.58M
Cash & Short-Term Investments $278.37K
Total Assets $127.62M
Current Ratio 0.51
Quick Ratio 0.51
Debt / Equity Ratio 0.14
Debt / EBITDA -0.27
Debt / FCF -1.05
OCF / Debt -0.95
Interest Coverage -4.47
Altman Z-Score -2.08
Piotroski F-Score 1
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -0.3%
Returns
Return on Assets -45.6%
Return on Equity -59.0%
Return on Invested Capital -15.9%
Return on Capital Employed -18.1%
Return on Tangible Assets -45.6%
Historical Growth (CAGR)
Revenue CAGR 3Y N/A
Revenue CAGR 5Y N/A
Revenue CAGR 10Y N/A
EPS CAGR 3Y -60.1%
EPS CAGR 5Y N/A
EPS CAGR 10Y N/A
FCF CAGR 3Y -103.4%
FCF CAGR 5Y N/A
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Hold
Analyst Count 0
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date Aug 14, 2026
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $0.00
Price Target Upside N/A
Cash Flow
Operating Cash Flow $-13.86M
Free Cash Flow $-13.92M
Adj. Free Cash Flow $-13.96M
FCF Per Share -$8.52
OCF Per Share -$8.49
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $-20.04K
Operating Income $-19.24M
EBITDA $-53.82M
Net Income $-58.17M
EPS (Diluted) -$49.29
Revenue / Employee N/A
Profit / Employee $-8.31M
Employees 7
Add to Watchlist
Select watchlists to add or remove APUS